ASPREE 亚组分析:阿司匹林未改善老年慢性肾脏病患者结局
该研究为 ASPREE 随机对照试验的事后亚组分析,比较每日 100 mg 肠溶阿司匹林与安慰剂。在 4758 例 CKD 患者与 13004 例非 CKD 参与者中,CKD 组复合终点、主要不良心血管事件及临床显著出血发生率近乎翻倍,阿司匹林在各结局上的效应在两组间基本一致,未改善结局且增加出血风险。
要点
- 老年 CKD 患者中阿司匹林未改善痴呆、持续残疾或死亡等复合终点。
- CKD 患者主要不良心血管事件与临床显著出血发生率近乎为非 CKD 者两倍。
- 阿司匹林在各结局上的效应在 CKD 与非 CKD 组间基本一致,且增加出血风险。
核心结论
- 在老年人群中,阿司匹林未改善结局且增加出血风险,CKD 与非 CKD 参与者中的效应基本一致。
研究设计与样本
- ASPREE 随机对照试验的事后亚组分析,比较每日 100 mg 肠溶阿司匹林与匹配安慰剂。
- 纳入社区居住成人:澳大利亚 70 岁及以上、美国 65 岁及以上,均无痴呆或心血管疾病史及预期 5 年内致死疾病。
- 基线 CKD 定义为 eGFR 低于 60 mL/min/1.73m2 或尿白蛋白与肌酐比值 3 mg/mmol 及以上。
- 分析样本为 4758 例 CKD 参与者与 13004 例非 CKD 参与者。
主要发现
- CKD 参与者的复合终点(痴呆、持续身体残疾或死亡)、主要不良心血管事件及临床显著出血发生率近乎为非 CKD 参与者的两倍。
- 以风险比估计,阿司匹林对痴呆、持续身体残疾或死亡、主要不良心血管事件及临床显著出血的效应在 CKD 与非 CKD 组间总体相似。
临床怎么用
- 老年 CKD 患者使用阿司匹林进行一级预防时,需权衡出血风险,不应期待改善痴呆、残疾或死亡等结局。
局限性
- 本研究为随机对照试验的事后亚组分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The role of aspirin for primary prevention in older adults with chronic kidney disease (CKD) is unclear. Therefore, post hoc analysis of the randomized controlled trial ASPirin in Reducing Events in the Elderly (ASPREE) was undertaken comparing 100 mg of enteric-coated aspirin daily against matching placebo. Participants were community dwelling adults aged 70 years and older in Australia, 65 years and older in the United States, all free of a history of dementia or cardiovascular disease and of any disease expected to lead to death within five years. CKD was defined as present at baseline if either eGFR under 60mL/min/1.73m2 or urine albumin to creatinine ratio 3 mg/mmol or more. In 4758 participants with and 13004 without CKD, the rates of a composite endpoint (dementia, persistent physical disability or death), major adverse cardiovascular events and clinically significant bleeding in the CKD participants were almost double those without CKD. Aspirin's effects as estimated by hazard ratios were generally similar between CKD and non-CKD groups for dementia, persistent physical disability or death, major adverse cardiovascular events and clinically significant bleeding. Thus, in our analysis aspirin did not improve outcomes in older people while increasing the risk of bleeding, with mostly consistent effects in participants with and without CKD.
引用
- Wolfe R, Wetmore JB, Woods RL, et al. Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. Kidney Int. 2020. PMID: 32920022. doi:10.1016/j.kint.2020.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。